Yeon Hee Park - Concepedia

Author

Yeon Hee Park

Also Known As

Dong Sook Kim, Doo Ho Choi, Hiroji Iwata, Korean Cancer Study Group (KCSG), Park, Yeon Hee, Seok Yun Kang, Sun-Kyeong Park, Y.H. Park, YEON HEE PARK, Yeon Hee Park

393

Publications

16.2K

Citations

H-Index

Concepts

All Affiliations

Samsung Medical Center Sungkyunkwan University Seoul National University Hospital Asan Medical Center Yonsei University

About

Yeon Hee Park is an author at Samsung Medical Center specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	59	3.6K
2	Health Sciences	16	21	1.1K
3	Public Health	3	3	276
4	Engineering	2	2	70
5	Nursing	1	1	28

Yeon Hee Park

132

Publications

15.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab for Early Triple-Negative Breast Cancer Peter Schmid, Javier Cortés, Lajos Pusztai, New England Journal of Medicine	2020	2.9K
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi, Cristina Saura, Toshinari Yamashita, New England Journal of Medicine	2019	1.9K
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer Woosung Chung, Hye Hyeon Eum, Hae‐Ock Lee, Nature Communications	2017	1K
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, New England Journal of Medicine	2023	600
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, The Lancet Oncology Phase 1/2Breast OncologyOncologyBasket StudyPathology	2020	435
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study Hope S. Rugo, Florence Lerebours, Eva Ciruelos, The Lancet Oncology Breast OncologyOncologyMedicinePathologyCdk4/6 Inhibitor	2021	340
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial Fabrice André, Yeon Hee Park, Sung‐Bae Kim, The Lancet Breast OncologyMedicineClinical TrialsBreast CancerPharmacotherapy	2023	313
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Peter Schmid, Javier Cortes, Rebecca Dent, New England Journal of Medicine	2024	310
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial Véronique Dièras, Hyo S. Han, Bella Kaufman, The Lancet Oncology Breast OncologyMedicinePharmacologyPathologyBreast Cancer	2020	306

Page 1